公开(公告)号：US20220289807A1

公开(公告)日：2022-09-15

申请号：US17634685

申请日：2020-08-13

Applicant: AMGEN INC.

Inventor： Darren L. BATES ,  Sue J. SOHN ,  Hannah Beth CATTERALL ,  Zhulun WANG

IPC: C07K14/55 ,  A61K38/20 ,  A61P3/10 ,  A61P37/06

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc fusion molecules that preferentially expand and activate cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20250066470A1

公开(公告)日：2025-02-27

申请号：US18435746

申请日：2024-02-07

Applicant: AMGEN INC.

Inventor： Sue J. SOHN ,  Marissa MOCK ,  Ian Nevin FOLTZ ,  Agnieszka KIELCZEWSKA ,  Kathy MANCHULENKO ,  Yannick BULLIARD ,  Xiaoshan MIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.

公开(公告)号：US20220017616A1

公开(公告)日：2022-01-20

申请号：US17375958

申请日：2021-07-14

Applicant: AMGEN INC.

Inventor： Sue J. SOHN ,  Marissa MOCK ,  Ian Nevin FOLTZ ,  Agnieszka KIELCZEWSKA ,  Kathy MANCHULENKO ,  Yannick BULLIARD ,  Xiaoshan MIN

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.